- OPKO Health (NASDAQ:OPK) rose 4.2% after a report speculated that the company could become a target following Roche's deal for GenMark Diagnostics (NASDAQ:GNMK) and as OPKO is pressured by an activist holder.
- OPKO, which is seeing some pressure from investor Sian Capital to sell its BioReference Labs unit, may potentially see interest from Quidel (NASDAQ:QDEL), which was reportedly in talks to do a transaction with Qiagen (QGEN), Dealreporter speculated today.
- Dealreporter also speculated Quest Diagnostics (NYSE:DGX) and LabCorp (NYSE:LH) could be potential buyers of OPKO's BioReference unit after Sian cited them as possible acquirers.
- Recall Feb. 24, LabCorp sum-of-the-parts worth $313/share with activist push, analyst says.